Andra AP fonden raised its stake in Merck & Co., Inc. (NYSE:MRK – Free Report) by 6.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 389,285 shares of the company’s stock after purchasing an additional 24,800 shares during the quarter. Andra AP fonden’s holdings in Merck & Co., Inc. were worth $50,023,000 at the end of the most recent reporting period.
A number of other institutional investors have also modified their holdings of MRK. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Bullseye Investment Management LLC purchased a new stake in shares of Merck & Co., Inc. in the second quarter valued at approximately $27,000. Graney & King LLC grew its holdings in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the period. Montgomery Financial Services LLC purchased a new position in Merck & Co., Inc. in the second quarter worth $41,000. Finally, Evergreen Advisors LLC purchased a new position in Merck & Co., Inc. in the first quarter worth $43,000. Institutional investors and hedge funds own 76.07% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on MRK. Wolfe Research boosted their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 25th. UBS Group raised their price objective on shares of Merck & Co., Inc. from $145.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Guggenheim increased their target price on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Royal Bank Of Canada downgraded shares of Merck & Co., Inc. from an “outperform” rating to a “sector perform” rating and lifted their price target for the company from $142.00 to $150.00 in a research report on Thursday, August 20th. Finally, The Goldman Sachs Group boosted their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. Seventeen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $154.24.
Key Headlines Impacting Merck & Co., Inc.
Here are the key news stories impacting Merck & Co., Inc. this week:
- Positive Sentiment: The U.S. FDA approved an update to the WINREVAIR label to include data from the Phase 3 HYPERION trial in recently diagnosed adults with pulmonary arterial hypertension. The expanded evidence may support broader adoption of the product and strengthens Merck’s growth prospects beyond KEYTRUDA. FDA approves WINREVAIR label update
- Positive Sentiment: Japan approved KEYTRUDA QLEX, Merck’s first subcutaneous KEYTRUDA formulation, for all locally approved KEYTRUDA indications. The faster, more convenient alternative to intravenous administration could improve patient and clinician convenience while helping defend KEYTRUDA’s international franchise. KEYTRUDA QLEX approved in Japan
- Positive Sentiment: The European Medicines Agency’s CHMP backed the KEYTRUDA-plus-PADCEV combination as a perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer. If formally approved, the decision would expand the combination’s addressable market and reinforce Merck’s oncology pipeline. CHMP backs Keytruda-Padcev combination
- Neutral Sentiment: The average sell-side recommendation remains equivalent to a Buy, but analyst optimism is not necessarily a reliable indicator of future performance. Investors should weigh the ratings against Merck’s earnings outlook, competitive risks and valuation. Analyst view on Merck
- Negative Sentiment: A separate analysis called Merck overvalued and overbought, highlighting potential profit-taking after the stock’s strong run. With shares near their 52-week high and a reported trailing P/E above 120, valuation remains a risk even as new product approvals improve the growth narrative. Merck valuation downgrade
Insider Buying and Selling
In other news, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the sale, the executive vice president directly owned 18,212 shares in the company, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares in the company, valued at approximately $6,073,631.14. The trade was a 63.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 228,238 shares of company stock valued at $29,977,783. Company insiders own 0.17% of the company’s stock.
Merck & Co., Inc. Price Performance
MRK traded up $1.78 during midday trading on Tuesday, reaching $151.28. 3,174,174 shares of the company’s stock were exchanged, compared to its average volume of 10,748,557. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The stock has a market capitalization of $373.23 billion, a PE ratio of 121.12, a P/E/G ratio of 6.39 and a beta of 0.21. The business’s 50-day moving average price is $138.97 and its 200 day moving average price is $125.44. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $156.92.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the business earned $2.13 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.
Merck & Co., Inc. Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.
About Merck & Co., Inc.
Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.
Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- IonQ’s AI Breakthrough Looks Big—But Can It Drive Revenue?
- Broadcom CEO Holds $350B Outlook Strong Amid Calls to Slow Froniter AI Development
- Microsoft’s 8% Dividend Hike: Confidence Signal or Distraction From Capex Math?
- Paramount Skydance Clears a Major Warner Bros. Discovery Hurdle—Here’s What Comes Next
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
